4.
To learn how to apply this tool in practice during guideline development. METHODS: The tool, consisting of a checklist of 'other considerations' and an instrument for grading recommendations, has been applied by the guideline working group drafting the revision of the evidence-based guideline on renal cell carcinoma. A literature search and synthesis of the evidence regarding 'other considerations' were carried out. RESULTS: The experiences of the guideline working group and the methodologist with the applied tool, as well as the search results and synthesis of the evidence on the 'other considerations,' were collected and evaluated. By using the tool to incorporate these considerations, it was transparent as to which were included in and how this affected the final recommendation. The revised guideline will be distributed to stakeholders to gain information on their perception of the process and results.
DISCUSSION (CONCLUSION):
Based on the experiences and commentaries of the guideline working group, methodologists, stakeholders, and users of the guideline, suggestions for improvement of the tool were extracted. After applying relevant changes, the tool will be implemented in oncologic guidelines within the Netherlands. Other organizations are invited to use this tool, which may lead to more structured and transparent guideline development. TARGET AUDIENCE(S): 1. Guideline developer 2. Guideline implementer 3. Developer of guideline-based products 4. Quality improvement manager/facilitator 5. Medical educator 6. Health care policy analyst/policymaker 7. Health insurance payers and purchasers 8. Medical providers and executives 9. Allied health professionals 10. Consumers' and patients' representatives 11. Nurses
SECONDARY TRACK: Grading BACKGROUND (INTRODUCTION):
At the 2009 conference it was reported that the Scottish Intercollegiate Guidelines Network is to adopt the GRADE approach to developing guideline recommendations. The progress that has been made since the decision was made to proceed is reported, and lessons learned so far are identified. LEARNING OBJECTIVES (TRAINING GOALS): 1. Highlight the key areas where existing methodology has to adapt to GRADE. 2. Identify the main stakeholder groups that need to be involved in major methodological changes. 3. Understand how implementing grading changes is as much about change management as methodology. 4. Consider ways of preparing guideline users for a major change in guideline presentation. METHODS: The approach taken to overcoming a number of methodological and organizational barriers is described. The new methodology has been integrated into the existing one through a process of iterative discussions, and new tools developed as necessary. A system of progressive training for guideline development group members has been introduced to ensure full understanding and uptake of the new system. RESULTS: The first groups to use the new approach started work in spring 2010, and will not complete it until 2011 at the earliest. Progress with involving staff and GDG members will be described. Steps taken to start preparing users for changes in the presentation of guideline recommendations and to explain the implications in terms of reliability of evidence and guidelines will be outlined. DISCUSSION (CONCLUSION): Changing the grading system involves a complete change of culture for an established organization such as SIGN. GRADE is a difficult system to explain in the abstract. Getting existing staff to accept the need for change and the potential benefits has proved challenging, but is an essential first step in getting the changes embedded in the guideline development process. Many of the lessons learned during this work will be applicable to guideline developers elsewhere in the world. TARGET AUDIENCE(S): 1. Guideline developer 2. Guideline implementer 3. Developer of guideline-based products 4. Quality improvement manager/facilitator 5. Consumers' and patients' representatives BACKGROUND (INTRODUCTION) : As more health technologies come into the market, there is often a lag before good-quality RCTs are conducted to access their efficacy. The standard GRADE pro software does not easily support evidence assessment of single-arm studies, which may form the evidence base for such technologies. As evidence-based guidelines should be based on 'best available' evidence, case series and registry data may be considered during the decision-making process, if that is the extent of the evidence base. This study describes how adapting GRADE to include evidence assessment of case series and registry data can be used to assist in the development of recommendations.
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LEARNING OBJECTIVES (TRAINING GOALS):
1. Adapting GRADE to include evidence from case series and registry data. 2. Understanding how a wider evidence base can be used to enhance discussion during the guideline development process. METHODS: The GRADE table was modified to allow for evidence assessment from case series and registry data to be included appropriately alongside RCT and observational studies for the same outcomes. Informal interviews with a few representatives from the guideline development group (GDG) were undertaken to determine the usefulness of the same. RESULTS: Such adaptation allowed the guideline development group to consider the 'best available' evidence during the development process. This guideline is currently in development, but the preliminary results show that adapting GRADE allows for consideration of the wider evidence base for clinical guidelines where the majority of the evidence is of very low quality. DISCUSSION (CONCLUSION): Recommendations in clinical guidelines are often made in the absence of highquality RCTs as they may often not be ethical or available. GRADE can be adapted to include different types of published evidence, allowing consideration of the wider evidence base. We will present the modified GRADE and discuss how it was used by the GDG. TARGET AUDIENCE(S): 1. Clinical researcher 2. Evidence synthesizer, developer of systematic reviews or meta-analyses 3. Guideline developer 4. Guideline implementer
